Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 6, 2026, 5:22 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 217–240 of 3,386 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Multiple Pathologies Clear all

Conditions: Paroxysmal Atrial Fibrillation
Interventions: FARAPULSE™ Pulsed Field Ablation System; Device
Lead sponsor: Boston Scientific Corporation; Industry
Eligibility: 18 Years and older
Enrollment: 228 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2029
U.S. locations: 25
States / cities: Mobile, Alabama • Scottsdale, Arizona • Oakland, California + 20 more

Conditions: Clostridium Infections, Methicillin-resistant Staphylococcus Aureus (MRSA), Vancomycin-Resistant Enterococci, Carbapenem-Resistant Enterobacteriaceae, Asymptomatic Infections
Interventions: Resistant Potato Starch, Maltodextrin; Drug
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: 18 Years and older
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2027 – 2030
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Chronic Hepatitis C
Interventions: valopicitabine, pegylated interferon; Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years to 65 Years
Timeline: Started 2004
U.S. locations: 2
States / cities: Bradenton, Florida • San Antonio, Texas

Conditions: Carcinoma, Metastatic Breast
Interventions: CPG 7909, Herceptin®; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2003
U.S. locations: 8
States / cities: Farmington, Connecticut • Plantation, Florida • Baltimore, Maryland + 5 more

Conditions: Metastatic Colorectal Cancer, Colon Cancer, Rectal Cancer
Interventions: 5- Fluorouracil (5-FU), bevacizumab (Avastin), Leucovorin, CoFactor (ANX-510); Drug
Lead sponsor: Mast Therapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 1,200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2006
U.S. locations: 46
States / cities: Florence, Alabama • Anaheim, California • Apple Valley, California + 41 more

Conditions: Urinary Incontinence
Interventions: Multi-modal rehabilitation program, Pelvic Floor Physical therapy; Other
Lead sponsor: Howard University; Other
Eligibility: 65 Years and older · Female only
Enrollment: 18 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2021
U.S. locations: 1
States / cities: Washington D.C., District of Columbia

Conditions: End Stage Renal Disease
Interventions: Empagliflozin 10 MG, Placebo; Drug
Lead sponsor: NYU Langone Health; Other
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 2
States / cities: Boston, Massachusetts • New York, New York

Conditions: Cardiovascular Health, Self-management
Interventions: Health360x plus health coach, Health360x only (High tech); Behavioral
Lead sponsor: Morehouse School of Medicine; Other
Eligibility: 21 Years to 70 Years
Enrollment: 150 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2021
U.S. locations: 2
States / cities: Atlanta, Georgia

Conditions: Multiple Sclerosis, Relapsing-Remitting, Multiple Sclerosis, Secondary Progressive
Interventions: Tovaxin Autologous T Cell Vaccine; Biological
Lead sponsor: Opexa Therapeutics, Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2008
U.S. locations: 2
States / cities: Bellaire, Texas • Houston, Texas

Conditions: Paroxysmal Atrial Fibrillation
Interventions: TactiCath SE; Device
Lead sponsor: Abbott Medical Devices; Industry
Eligibility: 18 Years and older
Enrollment: 156 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 14
States / cities: Little Rock, Arkansas • La Jolla, California • Redwood City, California + 10 more

Conditions: Children With Medical Complexity
Interventions: MyChildCMC app; Other
Lead sponsor: University of Utah; Other
Eligibility: 1 Year to 20 Years
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: Salt Lake City, Utah

Conditions: Kidney Failure, Chronic, Hemodialysis Complication, Hemodialysis Catheter Infection, Hemodialysis Access Failure, Central Venous Catheter Related Bloodstream Infection, End Stage Renal Disease
Interventions: Pristine™ Long-Term Hemodialysis Catheter; Device
Lead sponsor: C. R. Bard; Industry
Eligibility: 18 Years and older
Enrollment: 142 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022
U.S. locations: 6
States / cities: Dothan, Alabama • New Haven, Connecticut • Shreveport, Louisiana + 3 more

Conditions: Multiple Sclerosis, Fatigue
Interventions: High Dose Aspirin (1300 mg/day), Low Dose Aspirin (162 mg/day), Placebo; Drug
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years to 65 Years
Enrollment: 62 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2013
U.S. locations: 1
States / cities: Scottsdale, Arizona

Conditions: Obesity or Overweight
Interventions: RO7795081, Placebo; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years and older
Enrollment: 352 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 36
States / cities: Anniston, Alabama • Lake Forest, California • Rancho Cucamonga, California + 31 more

Conditions: AML/MDS, CD33 Expressing Hematological Malignancies, FLT3 Expressing Hematological Malignancies
Interventions: SENTI-202; Biological
Lead sponsor: Senti Biosciences; Industry
Eligibility: 18 Years to 74 Years
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2040
U.S. locations: 6
States / cities: Los Angeles, California • Denver, Colorado • Jacksonville, Florida + 3 more

Conditions: Chronic Pain, Back Pain
Interventions: Spectra WaveWriter SCS System; Device
Lead sponsor: Boston Scientific Corporation; Industry
Eligibility: 22 Years and older
Enrollment: 97 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 15
States / cities: Napa, California • Jupiter, Florida • Ocala, Florida + 12 more

Conditions: Multiple Myeloma
Interventions: CC-92480, Dexamethasone; Drug
Lead sponsor: Celgene; Industry
Eligibility: 18 Years and older
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2025
U.S. locations: 10
States / cities: Duarte, California • Atlanta, Georgia • Boston, Massachusetts + 7 more

Conditions: Kidney Disease, Chronic
Interventions: BI 690517, Placebo to BI 690517, Empagliflozin, Placebo to empagliflozin; Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 18 Years and older
Enrollment: 714 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 41
States / cities: Mesa, Arizona • Phoenix, Arizona • Canyon Country, California + 34 more

Conditions: Sjögren Syndrome
Interventions: Remibrutinib, Placebo; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 73 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Acute-On-Chronic Liver Failure, Ascites
Interventions: VS-01 on top of SOC, SOC (Control Group); Drug · Other
Lead sponsor: Genfit; Industry
Eligibility: 18 Years to 79 Years
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 13
States / cities: Sacramento, California • Washington D.C., District of Columbia • Tampa, Florida + 9 more

Conditions: Multiple Sclerosis
Interventions: Inhaled Cannabis, Oral THC, Oral Placebo, Inhaled placebo; Drug
Lead sponsor: University of California, Davis; Other
Eligibility: 21 Years and older
Enrollment: 41 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2011
U.S. locations: 1
States / cities: Sacramento, California

Conditions: Oxygen Deficiency, Desaturation of Blood, Hypoventilation, Anesthesia; Adverse Effect
Interventions: Transnasal Humidified Rapid-Insufflation Ventilatory Echange; Device
Lead sponsor: Stanford University; Other
Eligibility: Up to 18 Years
Enrollment: 175 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2024
U.S. locations: 5
States / cities: Palo Alto, California • Chicago, Illinois • Boston, Massachusetts + 2 more

Conditions: Relapsing-Remitting Multiple Sclerosis, Secondary Progressive Multiple Sclerosis
Interventions: natalizumab, standard of care; Drug · Other
Lead sponsor: Biogen; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 76 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2011
U.S. locations: 12
States / cities: Phoenix, Arizona • Scottsdale, Arizona • Berkeley, California + 9 more

Conditions: Bladder, Neurogenic
Interventions: tamsulosin hydrochloride, Placebo; Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 2 Years to 16 Years
Enrollment: 231 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 7
States / cities: Los Angeles, California • Tampa, Florida • St Louis, Missouri + 4 more

Search by objective public record fields.

ADVENT Post Approval Study

A Clinical Trial of Resistant Potato Starch for Gut MDRO Decolonization

Valopicitabine When Administered Alone and in Combination With Interferon to Treatment-Naive Patients With Hepatitis C

Safety And Efficacy Study Of The Combination Of CpG 7909 And Herceptin In Patients With Metastatic Breast Cancer

Phase III Randomized Study of 5-FU, CoFactor, and Avastin vs. 5-FU, LV and Avastin for First-Line Colorectal Cancer.

Functional Assessment and Muscle Evaluation Through Exercise Trial

Safety and Efficacy of Empagliflozin in Hemodialysis

MECA Clinical Intervention ( MECA Health360x)

Dose-Escalation Study of T Cell Vaccine in Multiple Sclerosis

TactiSense IDE Trial of TactiCath SE for Paroxysmal Atrial Fibrillation

Self-management Intervention for Children With Chronic Medical Complexity: Pilot Feasibility Trial

The Pristine Post-Market Study

Aspirin for Treatment of Multiple Sclerosis-Related Fatigue

A Study Evaluating the Effect of Daily Oral RO7795081 in Participants With Obesity or Overweight With at Least One Weight-Related Comorbidity

SENTI-202: Off-the-shelf Logic Gated CAR NK Cell Therapy in Adults With CD33 and/or FLT3 Blood Cancers Including AML/MDS

Value of Multiple Modalities Using the Spectra WaveWriter Spinal Cord Stimulator System

A Safety, PK and Efficacy Study of CC-92480 Monotherapy and in Combination With Dexamethasone in Subjects With Relapsed and Refractory Multiple Myeloma (RRMM)

A Study to Test Whether Different Doses of BI 690517 Alone or in Combination With Empagliflozin Improve Kidney Function in People With Chronic Kidney Disease

A Phase 2 Study to Evaluate the Safety and Efficacy of LOU064 in Patients With Moderate to Severe Sjögren's Syndrome

Efficacy, Safety and Tolerability of VS-01 in Adult Patients With Acute-on-Chronic Liver Failure and Ascites (UNVEIL-IT)®

Cannabis for Spasticity in Multiple Sclerosis

THRIVE Use in Pediatric Populations- Multi Site

Safety Study of Natalizumab to Treat Multiple Sclerosis (MS)

Study to Evaluate the Efficacy and Safety of Tamsulosin in Children With Neurogenic Bladder